相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Article
Biochemistry & Molecular Biology
Wilfredo F. Garcia-Beltran et al.
Summary: Recent surveillance has identified the emergence of the SARS-CoV-2 Omicron variant, which carries up to 36 mutations in the spike protein and has the potential to evade vaccine-induced immunity. This study found that individuals vaccinated with mRNA vaccines exhibited strong neutralization of the Omicron variant, while most vaccinees had weak neutralization. The study also revealed that the Omicron variant infects more efficiently than other tested variants.
Article
Biochemistry & Molecular Biology
Markus Hoffmann et al.
Summary: The Omicron variant of SARS-CoV-2 is spreading rapidly and shows resistance to most therapeutic antibodies. It also evades neutralization by antibodies induced by infection or vaccination more efficiently than the Delta variant. This suggests that therapeutic antibodies may not be effective against the Omicron variant, and double vaccination with BNT162b2 may not provide adequate protection against severe disease caused by this variant.
Article
Multidisciplinary Sciences
Delphine Planas et al.
Summary: The Omicron variant of SARS-CoV-2, identified in November 2021, has spread rapidly worldwide and shows resistance to most therapeutic monoclonal antibodies and vaccine-elicited antibodies. However, it can be neutralized by antibodies generated by a booster vaccine dose.
Article
Multidisciplinary Sciences
Juan Manuel Carreno et al.
Summary: The Omicron variant of SARS-CoV-2, first identified in South Africa and Botswana in November 2021, has rapidly spread globally with high transmissibility. It has an unprecedented number of mutations in its spike gene, leading to immune escape and reduced vaccine efficacy. The neutralizing and binding activity against Omicron varies among individuals with different vaccination and infection histories.
Article
Multidisciplinary Sciences
Kang Wang et al.
Summary: The Omicron variant of SARS-CoV-2 is highly resistant to neutralizing antibodies, which raises concerns about the effectiveness of antibody therapies and vaccines. A study found that individuals who received two or three doses of an inactivated SARS-CoV-2 vaccine had varying rates of seroconversion for neutralizing antibodies. The effectiveness of neutralizing antibodies against Omicron was significantly lower in individuals who received three vaccine doses. However, monoclonal antibodies derived from individuals who received three vaccine doses showed strong neutralizing activity against all variants of concern, including Omicron.
Article
Biochemistry & Molecular Biology
Samuel M. S. Cheng et al.
Summary: Specific antibody levels against the SARS-CoV-2 Omicron variant decrease significantly after two doses of BNT162b2 or CoronaVac vaccines, but can be markedly increased with a booster dose of BNT162b2. Individuals who previously received two doses of BNT162b2 or CoronaVac showed reduced serum antibody titers against Omicron, while a BNT162b2 booster dose increased the antibody levels in the majority of individuals. This suggests mRNA vaccine boosters may be necessary in countries primarily using CoronaVac vaccines to combat the spread of Omicron.
Article
Biochemistry & Molecular Biology
Eddy Perez-Then et al.
Summary: The study found that a BNT162b2 mRNA vaccine booster can enhance neutralizing antibodies against the Omicron variant in individuals who received two doses of the CoronaVac vaccine, but antibody titers remain lower compared to the ancestral virus and the Delta variant.
Letter
Medicine, General & Internal
Annika Roessler et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Cell Biology
Benjamin L. Sievers et al.
Summary: This study demonstrates that the Omicron variant of SARS-CoV-2 is the most resistant to neutralization, and antibody responses may be reduced in vaccinated pregnant women, highlighting the need to maximize vaccine responses in this population.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Article
Immunology
Chengbao Ma et al.
Summary: The heavily mutated SARS-CoV-2 Omicron variant has raised global concern due to its emergence and rapid transmission. This study compared the infectivity, membrane fusion, and immune escape efficiency of the Omicron variant with the original strain and the Delta variant. The results showed that the Omicron variant had slightly higher infectivity and a significantly reduced fusogenicity compared to the Delta variant. Neutralization assays revealed a dramatic reduction in neutralization against the Omicron variant, but immune-boosting through three vaccine shots improved immunity against it.
EMERGING MICROBES & INFECTIONS
(2022)
Article
Cell Biology
Yihao Liu et al.
Summary: SARS-CoV-2 inactivated vaccines have demonstrated significant efficacy in reducing severe illness and death. Despite a decline in humoral immunity over time, memory B and T cells remain detectable and can provide a quick recall response. A third booster dose enhances the immune response and improves the durability of protective immunity. Additionally, healthcare workers with low serological response to two doses still possess immune memory that can be quickly recalled by a third dose.
Article
Immunology
Luca Coppeta et al.
Summary: This retrospective study evaluated the determinants of serological protection in vaccinated healthcare workers and found that 99.5% of them developed protective antibodies that were maintained for as long as 250 days after the second dose of the BNT162b2 vaccine. The antibody titer observed at the second evaluation was significantly related to the primary response, evaluation time interval, and previous history of SARS-CoV-2 infection. Importantly, none of the study participants contracted severe COVID-19 during the observation period.
Article
Virology
Tugba Y. Yalcin et al.
Summary: This study evaluated antibody levels after inactivated virus vaccination, finding that individuals previously infected with COVID-19 had higher antibody levels and longer duration of antibody response after a single vaccine dose. A positive correlation between IgGsp antibody titers and neutralizing capacity was also observed, suggesting that quantitative IgGsp values may reflect vaccine neutralization capacity.
JOURNAL OF MEDICAL VIROLOGY
(2022)
Article
Medicine, General & Internal
Nicolas A. Muena et al.
Summary: The decay of neutralizing antibody titres over time in previously infected individuals highlights the need for vaccination to boost immune responses. The real-life effectiveness of CoronaVac in a highly immunized population in Chile was higher than expected, suggesting that lower antibody titres and additional cellular immune responses induced by the vaccine might afford protection. However, the lower neutralizing antibody titres induced by two doses of CoronaVac compared to the BTN162b2 vaccine in naive individuals highlights the need for booster immunizations over time to maintain protective levels of antibody.
Review
Immunology
Brian J. Laidlaw et al.
Summary: The GC response is crucial in establishing durable and broad immunity against SARS-CoV-2, with emerging evidence suggesting new approaches to modulate GC response and long-term immune responses induced by vaccines. Importantly, GC B cell responses persist for at least 6 months in some individuals following SARS-CoV-2 vaccination.
NATURE REVIEWS IMMUNOLOGY
(2022)
Article
Infectious Diseases
Wan Ni Chia et al.
Summary: The study investigated the dynamics of neutralising antibody response in patients who have recovered from COVID-19, finding great variations and suggesting that predicting immune longevity can only be accurately determined at the individual level. The findings emphasize the importance of public health and social measures in the ongoing pandemic outbreak response, and may have implications for the longevity of immunity after vaccination.
Article
Infectious Diseases
Shengli Xia et al.
Summary: The inactivated SARS-CoV-2 vaccine, BBIBP-CorV, demonstrated safety and immunogenicity in two age groups. Humoral responses against SARS-CoV-2 were induced in all vaccine recipients by day 42. A two-dose immunisation with 4 mu g vaccine on days 0 and 21 or days 0 and 28 achieved higher neutralising antibody titres compared to other dosing schedules.
LANCET INFECTIOUS DISEASES
(2021)
Review
Immunology
Jeffrey Cohen et al.
Summary: The likelihood and duration of reinfection with SARS-CoV-2 remain uncertain, as current knowledge on this topic is limited. Studies on other respiratory viruses suggest that serum antibodies typically persist for only a few months to a few years, making reinfections common. These findings have implications for vaccine development and the need for continued protective measures.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Medicine, General & Internal
S. F. Lumley et al.
Summary: In a longitudinal study of seropositive and seronegative health care workers undergoing asymptomatic and symptomatic SARS-CoV-2 testing, the presence of anti-spike or anti-nucleocapsid IgG antibodies was associated with a substantially reduced risk of SARS-CoV-2 reinfection in the ensuing 6 months.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Infectious Diseases
Rivaldo Steven Heriyanto et al.
Summary: This study revealed that COVID-19 survivors and females had higher neutralizing antibody titers after receiving the Sinovac vaccine.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2021)
News Item
Multidisciplinary Sciences
Smriti Mallapaty
Article
Infectious Diseases
Yanjun Zhang et al.
Summary: This study investigated the safety, tolerability, and immunogenicity of the COVID-19 vaccine candidate CoronaVac, and found that the 3 μg dose showed higher seroconversion rates in the phase 2 trial.
LANCET INFECTIOUS DISEASES
(2021)
Article
Multidisciplinary Sciences
Jun Zhang et al.
Summary: The Delta variant of SARS-CoV-2 is more efficient at fusing membranes at low levels of cellular receptor ACE2, possibly contributing to its heightened transmissibility. Each variant shows different rearrangement of the antigenic surface of the S protein, but only the changes in the RBD make it a better target for therapeutic antibodies.
Article
Environmental Sciences
Luca Coppeta et al.
Summary: The study revealed a high prevalence of SARS-CoV-2 infection among hospital nurses at a Rome COVID hospital before the vaccination programmes commenced in 2021. Night shift work, smoking, young age, and high-risk hospital settings were identified as significant risk factors for hospital SARS-CoV-2 infection, highlighting the need for close health surveillance among exposed hospital nurses.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
(2021)
Article
Immunology
Annalisa Ciabattini et al.
Summary: The study found that spike-specific antibodies and memory B cells still persisted up to 6 months after BNT162b2 vaccine administration, indicating a lasting immune protection against SARS-CoV-2 virus.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Medicine, Research & Experimental
Suhas Sureshchandra et al.
Summary: mRNA vaccines for SARS-CoV-2 have shown strong protection against severe disease, enhancing spike-specific B cells and robust CD4(+) T cell responses. However, CD8(+) T cell responses following vaccination were relatively weak and variable, with clonally expanded CD8(+) T cells observed.
Article
Immunology
Rishi R. Goel et al.
Summary: mRNA vaccines exhibit robust serological and cellular priming, with naïve individuals requiring two doses for optimal antibody responses, especially against the B.1.351 variant. Memory B cells specific for spike protein and RBD were efficiently primed by vaccination, while recovered individuals showed significant boosting after the first dose, correlating with preexisting memory B cell levels. Identifying distinct responses based on prior SARS-CoV-2 exposure suggests that recovered subjects may only need one vaccine dose for peak responses, which can inform vaccine distribution strategies in resource-limited settings.
SCIENCE IMMUNOLOGY
(2021)
Letter
Immunology
Hao Wang et al.
CELLULAR & MOLECULAR IMMUNOLOGY
(2021)
Article
Immunology
Aurelien Sokal et al.
Summary: This study examined the MBC responses in recovered and naive individuals after mRNA vaccination against SARS-CoV-2, finding that the MBC pool in recovered individuals expanded selectively, matured further, and had potent neutralizers against VOCs. Naive individuals displayed weaker neutralizing serum responses, but a significant portion of their RBD-specific MBCs showed high affinity to multiple VOCs, suggesting potential efficient response to VOCs in naive vaccinees.
Article
Medicine, General & Internal
Nawal Al Kaabi et al.
Summary: This interim analysis of an ongoing randomized trial in the UAE and Bahrain evaluated the efficacy of two inactivated COVID-19 vaccines in preventing symptomatic cases and adverse events in healthy adults. The study found that both vaccines significantly reduced the risk of symptomatic COVID-19 compared to the control group, with efficacy rates of 72.8% and 78.1%. Serious adverse events were rare across all groups.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Editorial Material
Multidisciplinary Sciences
Muge Cevik et al.
Article
Immunology
Luca Coppeta et al.
Summary: The study evaluated the duration of serological protection among healthcare workers three months after vaccination, with 99% of them still having detectable anti-SARS-CoV-2 antibodies after 90 days of receiving the second vaccine shot. Elderly healthcare workers showed significantly lower levels of protective antibodies compared to younger ones, indicating they may lose immunity earlier than other operators.
Article
Medicine, General & Internal
Shengli Xia et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2020)
Editorial Material
Medicine, General & Internal
David S. Stephens et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2020)
Editorial Material
Multidisciplinary Sciences
Jeffrey Shaman et al.
Article
Public, Environmental & Occupational Health
Yelena Rozenfeld et al.
INTERNATIONAL JOURNAL FOR EQUITY IN HEALTH
(2020)
